



# Financial Tear Sheet

## Corporate Profile


MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

## Stock Information

### MYOK (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	<b>\$44.39</b>
Change (%)	▼ 1.13 (2.48%)
Volume	258,925
52 Week Low	\$39.16
Market Cap	\$1,833,122,765
Rolling EPS	-1.59
PE Ratio	0
Shares Outstanding	40,270,711

Data as of 01/22/19 4:00 p.m. ET



## Recent Press Releases

**01/03/19**

MyoKardia to Present at 37th Annual J.P. Morgan Healthcare Conference

**01/02/19**

MyoKardia Regains Global Rights to Mavacamten and MYK-491 Programs from Sanofi

**12/11/18**

## Upcoming Events

There are currently no events scheduled.

## SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads
01/11/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/09/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/09/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/09/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/09/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/09/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/08/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/03/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   
01/03/19	4	Statement of changes in beneficial ownership of securities	3,4,5	   

01/03/19

4

Statement of changes in beneficial  
ownership of securities

3,4,5



<< First | Previous | Next | Last >>

## Corporate Governance

Tassos Gianakakos Chief Executive Officer

Jonathan Fox, M.D., Ph.D. Chief Medical Officer

Jake Bauer Vice President, Business Development and Business Operations

Ingrid Boyes Senior Vice President, Human Resources

Steven Chan Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell Senior Vice President of Drug Discovery

Iris Roth, Ph.D. Vice President, Program Team Leader